Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, HC Wainwright Analyst Says

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective raised by HC Wainwright from $82.00 to $95.00 in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q1 2025 earnings at ($1.20) EPS and Q4 2025 earnings at ($0.96) EPS.

Several other equities research analysts also recently issued reports on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Thursday, September 26th. Wells Fargo & Company increased their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. TD Cowen increased their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Barclays lowered their price objective on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.69.

Ultragenyx Pharmaceutical Stock Down 3.2 %

Shares of Ultragenyx Pharmaceutical stock opened at $50.52 on Wednesday. Ultragenyx Pharmaceutical has a fifty-two week low of $34.06 and a fifty-two week high of $60.37. The firm has a market cap of $4.66 billion, a price-to-earnings ratio of -6.92 and a beta of 0.58. The business has a fifty day simple moving average of $55.32 and a 200-day simple moving average of $48.11.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The firm’s quarterly revenue was up 42.3% compared to the same quarter last year. During the same period last year, the firm posted ($2.23) earnings per share. Analysts anticipate that Ultragenyx Pharmaceutical will post -6.29 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,556 shares of company stock worth $1,515,967. Insiders own 5.80% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in RARE. Mutual of America Capital Management LLC bought a new position in shares of Ultragenyx Pharmaceutical during the third quarter valued at $321,000. Natixis Advisors LLC lifted its stake in Ultragenyx Pharmaceutical by 290.0% in the third quarter. Natixis Advisors LLC now owns 52,562 shares of the biopharmaceutical company’s stock valued at $2,920,000 after buying an additional 39,086 shares during the period. KBC Group NV boosted its stake in Ultragenyx Pharmaceutical by 24.5% during the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 506 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 8.8% in the 3rd quarter. Victory Capital Management Inc. now owns 10,948 shares of the biopharmaceutical company’s stock valued at $608,000 after buying an additional 884 shares during the period. Finally, Atria Investments Inc bought a new position in Ultragenyx Pharmaceutical in the third quarter worth approximately $269,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.